Monitoring the epidemiology of bloodstream infections: Aims, methods and importance

Expert Review of Anti-Infective Therapy

Volumn 11, Issue 12, 2013, Pages 1281-1290

  Søgaard, Mette ^a   Lyytikäinen, Outi ^b   Laupland, Kevin B ^c   Schønheyder, Henrik Carl ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c ROYAL INLAND HOSPITAL   (Canada)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bacteremia; Epidemiology; Monitoring; Outcome; Surveillance

Indexed keywords

ANTIBIOTIC SENSITIVITY; AUTOMATION; BLOOD CULTURE; BLOODSTREAM INFECTION; DISEASE SEVERITY; DISEASE SURVEILLANCE; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; MEDICAL INFORMATION SYSTEM; PUBLIC HEALTH; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

BACTEREMIA; DATA COLLECTION; EPIDEMIOLOGICAL MONITORING; EUROPE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; UNITED STATES;

EID: 84888030364     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2013.856262     Document Type: Review

References (92)

1. Libman E. John Hopkins Hospital Bulletin. John Hopkins Hosp. Bull. 27, 215 (1906).
2. Rhea L, Emmons A. A series of ninety-one consecutive blood cultures. Bost. Med. Surg. J. 157, 809-813 (1907).
3. Kirn TJ, Weinstein MP. Update on blood cultures: how to obtain, process, report, and interpret. Clin. Microbiol. Infect. 19(6), 513-520 (2013).
4. Skogberg K, Lyytikäinen O, Ollgren J, Nuorti JP, Ruutu P. Population-based burden of bloodstream infections in Finland. Clin. Microbiol. Infect. 18(6), E170-E176 (2012).
5. Skogberg K, Lyytikäinen O, Ruutu P, Ollgren J, Nuorti JP. Increase in bloodstream infections in Finland, 1995-2002. Epidemiol. Infect. 136(1), 108-114 (2008).
6. Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 320(7229), 213-216 (2000).
7. Goto M, Al-Hasan MN. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin. Microbiol. Infect. 19(6), 501-509 (2013).
8. Søgaard M, Nørgaard M, Dethlefsen C, Schønheyder HC. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study. Clin. Infect. Dis. 52(1), 61-69 (2011).
9. Laupland KB. Incidence of bloodstream infection: a review of population-based studies. Clin. Microbiol. Infect. 19(6), 492-500 (2013).
10. Kochanek K, Jiaguan X, Murphy S, Minino A, Hsiang-Ching K. Deaths: final data for 2009. Natl Vital. Stat. Rep. 60(3), 1-117 (2011).
11. De Kraker MEA, Jarlier V, Monen JCM, Heuer OE, van de Sande N, Grundmann H. The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin. Microbiol. Infect. 19(9), 860-868 (2013).
12. Sexton DJ, Chen LF, Moehring R, Thacker PA, Anderson DJ. Casablanca redux: we are shocked that public reporting of rates of central line-associated bloodstream infections are inaccurate. Infect. Control Hosp. Epidemiol. 33(9), 932-935 (2012).
13. Laupland KB. Defining the epidemiology of bloodstream infections: the "gold standard" of population-based assessment. Epidemiol. Infect., 1-9 (2012).
14. Langmuir AD. The surveillance of communicable diseases of national importance. N. Engl. J. Med. 268, 182-192 (1963).
15. McGowan JE, Barnes MW, Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J. Infect. Dis. 132(3), 316-335 (1975).
16. McGowan JE. Changing etiology of nosocomial bacteremia and fungemia and other hospital-acquired infections. Rev. Infect. Dis. 7(Suppl. 3), S357-S370.
17. Haley RW, Hooton TM, Culver DH et al. Nosocomial infections in U.S. hospitals, 1975-1976: estimated frequency by selected characteristics of patients. Am. J. Med. 70(4), 947-959 (1981).
18. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91(3B), 86S-89S (1991).
19. Weinstein MP, Reller LB, Murphy JR, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev. Infect. Dis. 5(1), 35-53 (1983).
20. Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II. Clinical observations, with special reference to factors influencing prognosis. Rev. Infect. Dis. 5(1), 54-70 (1983).
21. Martin CM. A national bacteremia registry. J. Infect. Dis. 120(4), 495-496 (1969).
22. Last J. A dictionary of epidemiology (4th Edition). Oxford University Press, NY, USA (2000).
23. Brown CS, Chand MA, Hoffman P et al. Possible contamination of organ preservation fluid with Bacillus cereus: the United Kingdom response. Euro Surveill. 17(18) (2012).
24. Brown DFJ, Hope R, Livermore DM et al. Non-susceptibility trends among enterococci and non-pneumococcal streptococci from bacteraemias in the UK and Ireland, 2001- 2006. J. Antimicrob. Chemother. 62(Suppl. 2), ii75-ii85 (2008).
25. Hope R, Livermore DM, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-2006. J. Antimicrob. Chemother. 62(Suppl. 2), ii65-ii74 (2008).
26. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J. Antimicrob. Chemother. 62(Suppl. 2), ii55-ii63 (2008).
27. Farrell DJ, Felmingham D, Shackcloth J et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland,1999. to 2007. J. Antimicrob. Chemother. 62(Suppl. 2), ii87-ii95 (2008).
28. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-2006. J. Antimicrob. Chemother. 62(Suppl. 2), ii41-ii54 (2008).
29. Pedersen G, Schønheyder HC, Sørensen HT. Antibiotic therapy and outcome of monomicrobial gram-negative bacteraemia: a 3-year population-based study. Scand. J. Infect. Dis. 29(6), 601-606 (1997).
30. Bates DW, Pruess KE, Lee TH. How bad are bacteremia and sepsis? Outcomes in a cohort with suspected bacteremia. Arch. Intern. Med. 155(6), 593-598 (1995).
31. Kumar A, Roberts D, Wood KE et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 34(6), 1589-1596 (2006).
32. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob. Agents Chemother. 54(11), 4851-4863 (2010).
33. Søgaard M, Nørgaard M, Pedersen L, Sørensen HT, Schønheyder HC. Blood culture status and mortality among patients with suspected community-acquired bacteremia: a population-based cohort study. BMC Infect. Dis. 11, 139 (2011).
34. Held L, Paul M. Statistical modeling of infectious disease surveillance data. In. Infectious Disease Surveillance. M'ikanatha NM, Lynfield R, Van Beneden CA, de Valk H (Eds). Wiley-Blackwell, West Sussex, UK, 535-544 (2013).
35. Buehler JW. Surveillance. In. Modern Epidemiology. Rothman KJ, Greenland S, Lash TL (Eds). Lippincott Williams & Wilkins, Philadelphia, 459-480 (2008).
36. Moran JL, Solomon PJ. Statistical process control of mortality series in the Australian and New Zealand Intensive Care Society (ANZICS) adult patient database: implications of the data generating process. BMC Med. Res. Methodol. 13(1), 66 (2013).
37. Unkel S, Farrington C, Garthwaite P, Robetson C, Andrews N. Statistical models for the detection of infectious disease outbreaks: a review. J. R. Stat. Soc. A 175(1), 49-82 (2012).
38. Robertson C, Nelson T, MacNab Y, Lawson A. Review of methods for space-time disease surveillance. Spat. Spatiotemporal Epidemiol. 1, 105-116 (2010).
39. Nurminen M. Linkage failures in ecological studies. World Health Stat. Q. 48(2), 78-84 (1995).
40. Jessen O, Rosendal K, Bülow P, Faber V, Eriksen KR. Changing staphylococci and staphylococcal infections. A ten-year study of bacteria and cases of bacteremia. N. Engl. J. Med. 281(12), 627-635 (1969).
41. Giske CG, Cornaglia G. Supranational surveillance of antimicrobial resistance: The legacy of the last decade and proposals for the future. Drug Resist. Updat. 13(4-5), 93-98 (2010).
42. Pfaller MA, Jones RN, Doern G V, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42(7), 1762-1770 (1998).
43. Diekema DJ, Pfaller MA, Jones RN et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29(3), 595-607 (1999).
44. Laupland KB, Schønheyder HC, Kennedy KJ et al. Rationale for and protocol of a multi-national populationbased bacteremia surveillance collaborative. BMC Res. Notes 2, 146 (2009).
45. Wilson a PR, Kiernan M. Recommendations for surveillance priorities for healthcare-associated infections and criteria for their conduct. J. Antimicrob. Chemother. 67(Suppl. 1), i23-i28 (2012).
46. German R, Lee L, Horan J, Milstein R, Pertowski C, Waller M. Updated guidelines for evaluating public health surveillance systems. Reccomendations from the guideline working group. MMWR Recomm. Reports RR13, 1-35 (2001).
47. Keramarou M, Evans MR. Completeness of infectious disease notification in the United Kingdom: a systematic review. J. Infect. 64(6), 555-564 (2012).
48. Doyle TJ, Glynn MK, Groseclose SL. Completeness of notifiable infectious disease reporting in the United States: an analytical literature review. Am. J. Epidemiol. 155(9), 866-874 (2002).
49. Schønheyder HC, Paul M. Placing the burden of bacteraemia in perspective. Clin. Microbiol. Infect. 19(6), 489-91 (2013).
50. Steckelberg JM, Melton LJ, Ilstrup DM, Rouse MS, Wilson WR. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am. J. Med. 88(6), 582-588 (1990).
51. Al-Hasan MN, Eckel-Passow JE, Baddour LM. Influence of referral bias on the clinical characteristics of patients with Gram-negative bloodstream infection. Epidemiol. Infect. 139(11), 1750-1756 (2011).
52. Søgaard M, Engebjerg MC, Lundbye-Christensen S, Schønheyder HC. Changes in blood culture methodology have an impact on time trends of bacteraemia: a 26-year regional study. Epidemiol. Infect. 139(5), 772-776 (2011).
53. Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: how many blood cultures are needed. J. Clin. Microbiol. 45(11), 3546-3548 (2007).
54. Bouza E, Sousa D, Rodríguez-Créixems M, Lechuz JG, Muñoz P. Is the volume of blood cultured still a significant factor in the diagnosis of bloodstream infections. J. Clin. Microbiol. 45(9), 2765-2769 (2007).
55. Cockerill FR, Wilson JW, Vetter EA et al. Optimal testing parameters for blood cultures. Clin. Infect. Dis. 38(12), 1724-1730 (2004).
56. Coburn B, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood cultures? 308(5), 502-511 (2012).
57. Shapiro NI, Wolfe RE, Wright SB, Moore R, Bates DW. Who needs a blood culture? A prospectively derived and validated prediction rule. J. Emerg. Med. 35(3), 255-264 (2008).
58. Niedner MF. The harder you look, the more you find: Catheter-associated bloodstream infection surveillance variability. Am. J. Infect. Control. 38(8), 585-595 (2010).
59. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357(9260), 950-952 (2001).
60. Flasche S, Slack M, Miller E. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Euro Surveill. 16(20),19868. (2011).
61. Modi N, Doré CJ, Saraswatula a et al. A case definition for national and international neonatal bloodstream infection surveillance. Arch. Dis. Child. Fetal Neonatal Ed. 94(1), F8-F12 (2009).
62. Mayer J, Greene T, Howell J et al. Agreement in classifying bloodstream infections among multiple reviewers conducting surveillance. Clin. Infect. Dis. 55(3), 364-370 (2012).
63. Leal J, Gregson DB, Ross T, Flemons WW, Church DL, Laupland KB. Development of a novel electronic surveillance system for monitoring of bloodstream infections. Infect. Control Hosp. Epidemiol. 31(7), 740-747 (2010).
64. Gradel KO, Knudsen JD, Arpi M, Ostergaard C, Schønheyder HC, Søgaard M. Classification of positive blood cultures: computer algorithms versus physicians' assessment - development of tools for surveillance of bloodstream infection prognosis using population-based laboratory databases. BMC Med. Res. Methodol. 12(1),139. (2012).
65. Siegman-Igra Y, Ernst C. Nosocomial bloodstream infections: are positive blood cultures misleading. Clin. Infect. Dis. 30(6),986. (2000).
66. Beekmann SE, Diekema DJ, Doern G V. Determining the clinical significance of coagulase-negative staphylococci isolated from blood cultures. Infect. Control Hosp. Epidemiol. 26(6), 559-566 (2005).
67. Magee JT. Effects of duplicate and screening isolates on surveillance of community and hospital antibiotic resistance. J. Antimicrob. Chemother. 54(1), 155-162 (2004).
68. Wurtz R, Cameron BJ. Electronic laboratory reporting for the infectious diseases physician and clinical microbiologist. 60611 (2005).
69. Effler P, Ching-Lee M, Bogard A, Ieong MC, Nekomoto T, Jernigan D. Statewide system of electronic notifiable disease reporting from clinical laboratories: comparing automated reporting with conventional methods. JAMA 282(19), 1845-1850 (1999).
70. Overhage JM, Grannis S, McDonald CJ. A Comparison of the Completeness and Timeliness of Automated Electronic Laboratory Reporting and Spontaneous Reporting of Notifiable Conditions. Am. J. Public Health. 98(2), 344-350 (2008).
71. Elkin PL, Trusko BE, Koppel R, Speroff T. Secondary use of clinical data. Stud. Health Technol. Inform. 14-29 (2010).
72. Bean NH, Martin SM. Implementing a network for electronic surveillance reporting from public health reference laboratories?: an international perspective. Emerg Infect. Dis. 7(5), 773-779 (2001).
73. Panackal AA, Nkuchia MM, Tsui F et al. Automatic electronic laboratory-based reporting of notifiable infectious diseases at a large health system. Emerg Infect. Dis. 8(7), 685-691 (2002).
74. Trick WE, Zagorski BM, Tokars JI et al. Computer algorithms to detect bloodstream infections. Emerg. Infect. Dis. 10(9), 1612-1620 (2004).
75. Leal J, Laupland KB. Validity of electronic surveillance systems: a systematic review. J. Hosp. Infect. 69(3), 220-229 (2008).
76. Graham PL, San Gabriel P, Lutwick S, Haas J, Saiman L. Validation of a multicenter computer-based surveillance system for hospital-acquired bloodstream infections in neonatal intensive care departments. Am. J. Infect. Control. 32(4), 232-234 (2004).
77. Dixon BE, Mcgowan JJ, Grannis SJ. Electronic laboratory data quality and the value of a health information exchange to support public health reporting processes. AMIA Annu. Symp. Proc. (10), 322-330 (2011).
78. Bayer R, Fairchild AL. Public health. Surveillance and privacy. Science 290(5498), 1898-1899 (2000).
79. Bulloch W. The history of bacteriology. Dover Publication Inc, NY, USA (1979).
80. Bryan CS, Hornung CA, Reynolds KL, Brenner ER. Endemic bacteremia in Columbia, South Carolina. Am. J. Epidemiol. 123(1), 113-127 (1986).
81. Filice GA, Van Etta LL, Darby CP, Fraser DW. Bacteremia in Charleston County, South Carolina. Am. J. Epidemiol. 123(1), 128-136 (1986).
82. McGowan JE, Barnes MW, Finland M. Bacteremia at Boston City Hospital: Occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J. Infect. Dis. 132(3), 316-335 (1975).
83. Gransden WR, Eykyn SJ, Phillips I. Staphylococcus aureus bacteraemia:400. episodes in St Thomas's Hospital. Br. Med. J. (Clin. Res. Ed). 288(6413), 300-303 (1984).
84. Leibovici L, Konisberger H, Pitlik SD, Samra Z, Drucker M. Predictive index for optimizing empiric treatment of gram-negative bacteremia. J. Infect. Dis. 163(1), 193-196 (1991).
85. O'Brien TF, Stelling J. Integrated Multilevel Surveillance of the World's Infecting Microbes and Their Resistance to Antimicrobial Agents. Clin. Microbiol. Rev. 24(2), 281-295 (2011).
86. Medical Subject Headings. U.S. National Library of Medicine [Internet]. www.nlm.nih.gov/mesh/meshhome.html.
87. Instituttet for Hälsa och Välfärd (National Institute for Health and Welfare). www.thl.fi/en-US/web/en (Acssessed 8 July 2013)
88. Public Health England. www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/Bacteraemia/ (Acssessed 8 July 2013).
89. Surveillance in Denmark. Statens Serum Institut. www.ssi.dk/English/ HealthdataandICT/Surveillance in Denmark.aspx (Acssessed 8 July 2013)
90. Norwegian Surveillance System for Communicable Diseases (MSIS). Folkehelseinstituttet. www.fhi.no/eway/default.aspx?pid=240&trg=Main- 6664&Main-6664=6898:0:25,7846:1:0:0:::0:0 (Acssessed 8 July 2013)
91. Smittskyddsinstitutet (Smi) (Swedish Institute for Communicalble Disease Control). www.smittskyddsinstitutet.se/ (Acssessed 8 July 2013)
92. European Antimicrobial Resistance Surveillance Network (EARS-Net). www.ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/index.aspx (Acssessed 8 July 2013)